Free Trial

Ionis Pharmaceuticals (IONS) Earnings Date, Estimates & Call Transcripts

Ionis Pharmaceuticals logo
$38.76
+0.37 (+0.96%)
(As of 11/1/2024 ET)

Ionis Pharmaceuticals Latest Earnings Summary

Upcoming Q3
Earnings Date
Nov. 6Before Market OpensConfirmed
Actual EPS
(Aug. 1)
-$0.45 Beat By $0.47
Consensus EPS
(Aug. 1)
-$0.92

Ionis Pharmaceuticals released Q2 2024 earnings on August 1, 2024, reporting an EPS of -$0.45, which topped the consensus estimate of -$0.92 by $0.47. Quarterly revenue rose 19.7% year-over-year to $225 million, above analysts' expectations of $152.35 million. With a trailing EPS of -$2.52, Ionis Pharmaceuticals' earnings are expected to grow next year, from ($3.73) to ($3.54) per share.

IONS Upcoming Earnings

Ionis Pharmaceuticals' next earnings date is scheduled for Wednesday, November 6, 2024, with a conference call scheduled for at 11:30 AM ET. Interested parties can register for or listen to the call.

Get Ionis Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ionis Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

IONS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IONS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ionis Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243-$0.85-$0.72-$0.80
Q2 20243-$1.05-$0.74-$0.87
Q3 20243-$1.04-$0.91-$0.98
Q4 20243-$1.15-$0.55-$0.76
FY 202412-$4.09-$2.92-$3.41
Q1 20251-$1.13-$1.13-$1.13
Q2 20251-$0.95-$0.95-$0.95
Q3 20251-$0.93-$0.93-$0.93

Ionis Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/6/2024
(Confirmed)
-------  
8/1/2024Q2 2024-$0.92-$0.45+$0.47-$0.45$152.35M$225.00M        
5/7/2024Q1 2024-$1.10-$0.98+$0.12-$0.98$131.42M$119.00M    
2/21/2024Q4 2023-$0.78-$0.06+$0.72-$0.06$176.01M$325.00M          
11/2/2023Q3 2023-$1.01-$1.03 -$0.02-$1.03$139.42M$144.00M    
8/9/2023Q2 2023-$0.94$0.60+$1.54$0.60$136.84M$188.00M        
5/3/2023Q1 2023-$1.00-$0.87+$0.13-$0.87$126.88M$131.00M          
2/22/2023Q4 2022-$1.06-$0.37+$0.69-$0.37$160.21M$152.00M          
11/9/2022Q3 2022-$0.74-$0.33+$0.41-$0.33$149.48M$160.00M    

Ionis Pharmaceuticals Earnings - Frequently Asked Questions

Ionis Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Wednesday, November 6th, 2024. Learn more on IONS's earnings history.

In the previous quarter, Ionis Pharmaceuticals (NASDAQ:IONS) reported ($0.45) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.92) by $0.47. Learn more on analysts' earnings estimate vs. IONS's actual earnings.

The conference call for Ionis Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Ionis Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Ionis Pharmaceuticals (NASDAQ:IONS) has a recorded annual revenue of $788 million.

Ionis Pharmaceuticals (NASDAQ:IONS) has a recorded net income of -$366.29 million. IONS has generated -$2.52 earnings per share over the last four quarters.

Ionis Pharmaceuticals's earnings are expected to grow from ($3.73) per share to ($3.54) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:IONS) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners